The U.S. FDA has approved Merck's Keytruda Qlex, the first subcutaneous injection formulation of its blockbuster anti-PD-1 immunotherapy. This new product enables administration in about a minute rather than the traditional 30-minute intravenous infusion, potentially improving patient convenience and clinic workflow. The approval is supported by clinical trials demonstrating comparable efficacy and safety to the intravenous version. Keytruda remains a top-selling oncology drug, and this advancement could broaden its accessibility and appeal.